Treatment of HCV-Related Mixed Cryoglobulinemia Vasculitis According to the Presentation - Flowchart
Treatment of HCV-Related Mixed Cryoglobulinemia Vasculitis According to the Presentation - Flowchart Cryoglobulinemia Cryoglobulinemia
«Flowchart»

HCV Cryoglobulinemia Vasculitis

Therapeutic strategies

HCV Cryoglobulinemia Vasculitis

Therapeutic strategies

HCV Cryoglobulinemia Vasculitis

HCV Cryoglobulinemia Vasculitis

Therapeutic strategies

Therapeutic strategies

Mild, moderate

Arthralgia, purpura, polyneuropathy

Mild, moderate

Mild, moderate

Arthralgia, purpura, polyneuropathy

Mild, moderate

Severe

Renal disease, mononeuropathy multiplex, skin necrosis

Severe

Severe

Renal disease, mononeuropathy multiplex, skin necrosis

Severe

Catastrophic

Rapidly progressive GN, CNS, digestive, pulmonary involvement

Catastrophic

Catastrophic

Rapidly progressive GN, CNS, digestive, pulmonary involvement

Catastrophic

Rituximab, PE, IV steroids

Optimized antivirals (differed)

Rituximab, PE, IV steroids

Optimized antivirals (differed)

Rituximab, PE, IV steroids

Optimized antivirals (differed)

Rituximab

Then, optimized antivirals

Rituximab

Then, optimized antivirals

Rituximab

Then, optimized antivirals

Optimized antivirals

Optimized antivirals

Optimized antivirals

End

End

End

CNS, Central nervous system; GN, glomerulonephritis; HCV, hepatitis C virus; IV, intravenous; PE, pulmonary embolism.

CNS, Central nervous system; GN, glomerulonephritis; HCV, hepatitis C virus; IV, intravenous; PE, pulmonary embolism.

CNS, Central nervous system; GN, glomerulonephritis; HCV, hepatitis C virus; IV, intravenous; PE, pulmonary embolism.

CNS GN HCV IV PE